Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

Eva González-Barca, MD PhD, Johannes Duell, MD, Federica Cavallo, Juan-Manuel Sancho, MD PhD, Zsolt Nagy, MD PhD, Pau Abrisqueta, MD PhD, Carlos Panizo, MD PhD, Marinela Augustin, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Kami J. Maddocks, MD, Nagesh Kalakonda, MD, Gilles Salles, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-140294

Published: 2020

Journal Articles

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, Anna Marina Liberati, MD, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MDPhD, Gianluca Gaidano, Pau Abrisqueta, MD PhD, Marc André, MD, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles Salles, MDPhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-140314

Published: 2020

Journal Articles

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Blood (2019) 134 (Supplement_1): 5473.

https://doi.org/10.1182/blood-2019-126588

Published: 2019

Journal Articles

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Deborah A. Katz, MD, Michael P. Chu, Kevin A. David, MD, Catherine Thieblemont, MD PhD, Nicholas J. Morley, Sharif S. Khan, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González-Barca, MD PhD

Blood (2019) 134 (Supplement_1): 4077.

https://doi.org/10.1182/blood-2019-121708

Published: 2019

Journal Articles

Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

Maite Antonio, MD PhD, Montserrat Arnan Sangerman, MD PhD, Eva Domingo-Domenech, MD, Eva González-Barca, MD PhD, Casimiro Javierre, MD PhD, Laura Hurtos, Judit Sola, Anna Sureda, MD PhD, Josep Maria Borras, MD PhD

Blood (2019) 134 (Supplement_1): 3424.

https://doi.org/10.1182/blood-2019-129908

Published: 2019

Journal Articles

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, MD, Kami J. Maddocks, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MD PhD, Anna Marina Liberati, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MD PhD, Gianluca Gaidano, MD PhD, Pau Abrisqueta, MD PhD, Marc André, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles A. Salles, MD PhD

Blood (2019) 134 (Supplement_1): 1582.

https://doi.org/10.1182/blood-2019-122573

Published: 2019

Journal Articles

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Blood (2019) 134 (Supplement_1): 4296.

https://doi.org/10.1182/blood-2019-128470

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Blood (2019) 134 (Supplement_1): 752.

https://doi.org/10.1182/blood-2019-122191

Published: 2019

Journal Articles

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Blood (2018) 132 (Supplement 1): 1637.

https://doi.org/10.1182/blood-2018-99-110792

Published: 2018

Journal Articles

Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 5383.

https://doi.org/10.1182/blood-2018-99-111578

Published: 2018

Journal Articles

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Gilles Andre Salles, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MDPhD, Anna Marina Liberati, MD, Zsolt Nagy, MD PhD, Aleš Obr, MD, Gianluca Gaidano, MD PhD, Marc Andre, MDPhD, Nagesh Kalakonda, MD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Kami J. Maddocks, MD

Blood (2018) 132 (Supplement 1): 227.

https://doi.org/10.1182/blood-2018-99-113399

Published: 2018

Journal Articles

Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Blood (2017) 130 (Supplement 1): 2025.

https://doi.org/10.1182/blood.V130.Suppl_1.2025.2025

Published: 2017

Journal Articles

Validation of the NCCN-IPI and the Geltamo-IPI in a Large Cohort of Patients Diagnosed of Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP/R-CHOP-like in a Single Institution

Maria Queralt Salas Gay, MD, Santiago Mercadal, MD, Eva Domingo Domenech, MD, Ana C Oliveira, MD PhD, Maite Encuentra, Fina Climent, MD PhD, Cristina Baca Cano, MD, Marcio Andrade-Campos, MD PhD, Esmeralda De la Banda, MD, Carmen Aguilera, Alberto Fernandez de Sevilla, MD PhD, Anna Sureda, Eva González-Barca, MD PhD

Blood (2017) 130 (Supplement 1): 4151.

https://doi.org/10.1182/blood.V130.Suppl_1.4151.4151

Published: 2017

Journal Articles

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Gilles Andre Salles, MD PhD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, PhDMD, Anna Marina Liberati, MD, Zsolt Nagy, MD PhD, Tomáš Papajik, MD PhD, Gianluca Gaidano, MD PhD, Marc Andre, MD, Nagesh Kalakonda, MD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Sumeet Ambarkhane, MD, Johannes Weirather, PhD, Maren Dirnberger-Hertweck, PhD, Kami J. Maddocks, MD

Blood (2017) 130 (Supplement 1): 4123.

https://doi.org/10.1182/blood.V130.Suppl_1.4123.4123

Published: 2017

Journal Articles

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

Eva Gonzalez-Barca, MD PhD, Maria Queralt Salas Gay, MD, Francisco Javier Capote Huelva, Jose Gomez Codina, Carlos Panizo, MD PhD, Antonio Salar, MD PhD, Eva Domingo Domenech, MD, Alicia Bailen, Josep-Maria Ribera, MD, Andres Lopez, Javier Briones, MD, Andres Muñoz, Maite Encuentra, Alberto Fernandez de Sevilla, MD PhD

Blood (2017) 130 (Supplement 1): 1545.

https://doi.org/10.1182/blood.V130.Suppl_1.1545.1545

Published: 2017

Journal Articles

Abnormal Karyotype (Not Only Complex) at Diagnosis Is an Independent Prognostic Factor for Overall Survival in Early Stage Chronic Lymphocytic Leukemia Patients. Results of a Prospective Study with a Median Follow-up of More Than 7-Years

Ana C Oliveira, MD PhD, Esmeralda De la Banda, MD, Eva Domingo Domenech, MD, Isabel Granada, PhD, Alberto Fernandez de Sevilla, MD PhD, Santiago Mercadal, MD, Marcio Andrade-Campos, MD PhD, Maite Encuentra, Carmen Aguilera, Anna Sureda, Eva González-Barca, MD PhD

Blood (2017) 130 (Supplement 1): 5142.

https://doi.org/10.1182/blood.V130.Suppl_1.5142.5142

Published: 2017

Journal Articles

Lenalidomide in Combination with R-ESHAP (LR-ESHAP) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Candidates for Autologous Stem-Cell Transplantation: A Phase 2 Study from the Spanish Group Geltamo

Alejandro Martín, MD PhD, Mónica Baile, MD, Guillermo Rodríguez, MD, Ivan Dlouhy, MD, Juan Manuel Sancho, MD PhD, Isidro Jarque, MD, Eva González-Barca, MD PhD, Antonio Salar, MD PhD, Manuel Espeso, Carlos Grande, MD PhD, Juan Bergua, MD, Santiago Montes-Moreno, MD, Armando Lopez-Guillermo, Dolores Caballero, MD PhD

Blood (2016) 128 (22): 1850.

https://doi.org/10.1182/blood.V128.22.1850.1850

Published: 2016

Journal Articles

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

Juan-Manuel Sancho, Francisco Gual, Rubén Fernández-Alvarez, Esther González-García, MD, Carlos Grande, MD PhD, Carmen Jiménez-López, Norma C Gutierrez, MD PhD, María-José Peñarrubia, Ana Batlle, Eva González-Barca, MD PhD, Jose-Maria Guinea-de-Castro, Eva Gimeno, MD PhD, Francisco-Javier Peñalver, MD, Miguel A Fuertes, Jorge Gayoso, MD, José-Ángel Hernández-Rivas, José-María Moraleda, MD PhD, Lluis Virgili, Alejandro Martín, MD PhD

Blood (2016) 128 (22): 5387.

https://doi.org/10.1182/blood.V128.22.5387.5387

Published: 2016

Journal Articles

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Blood (2016) 128 (22): 4201.

https://doi.org/10.1182/blood.V128.22.4201.4201

Published: 2016

Journal Articles

Primary Cutaneous Marginal Zone B-Cell Lymphoma Treated with Intralesional Rituximab: Experience of a Single Center

Eva Domingo-Domenech, MD, Queralt Salas, MD, Fina Climent, MD PhD, Carmen Aguilera, Mrs, Helena Pomares, MD, Eva González-Barca, MD PhD, Santiago Mercadal, MD, Anna Lucas, MD, Alberto Fernandez de Sevilla, MD PhD, Anna Sureda, MD PhD, Octavio Servitje, MD PhD

Blood (2015) 126 (23): 5087.

https://doi.org/10.1182/blood.V126.23.5087.5087

Published: 2015

NARROW

Efficacy of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with High-Risk Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the L-Mind Study

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma

Impact of a Tailored Nutritional and Physical Exercise Programme on Efficacy and Functional Outcomes in Older Patients with Hematological Malignancies Classified By Frailty Profile

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group

Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Validation of the NCCN-IPI and the Geltamo-IPI in a Large Cohort of Patients Diagnosed of Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP/R-CHOP-like in a Single Institution

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Long-Term Follow-up of a Prospective Phase II Trial of Extended Treatment with Rituximab in Patients with B-Cell Post-Transplant Lymphoproliferative Disease and Comparison with a Cohort of Patients Treated in Real Life. Analysis on Behalf of the Spanish Lymphoma Group (GELTAMO)

Abnormal Karyotype (Not Only Complex) at Diagnosis Is an Independent Prognostic Factor for Overall Survival in Early Stage Chronic Lymphocytic Leukemia Patients. Results of a Prospective Study with a Median Follow-up of More Than 7-Years

Lenalidomide in Combination with R-ESHAP (LR-ESHAP) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Candidates for Autologous Stem-Cell Transplantation: A Phase 2 Study from the Spanish Group Geltamo

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Primary Cutaneous Marginal Zone B-Cell Lymphoma Treated with Intralesional Rituximab: Experience of a Single Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only